Skip to content

Syndax Pharmaceuticals SNDX Investment Purchases

Investment Purchases at other companies

Biogen logo
BiogenBIIB
$748.8M
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$64.38M+556%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$91.32M+28.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$131M
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$222.18M+274%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$177.29M

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.74B+95.0%
Enterprise value$1.96B+84.0%
P/S-12.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's investment purchases?
Syndax Pharmaceuticals (SNDX) reported investment purchases of $39.39M in Q1 2026.
How has Syndax Pharmaceuticals's investment purchases changed year-over-year?
Syndax Pharmaceuticals's investment purchases increased by 273.8% year-over-year, from $10.54M to $39.39M.
What is the long-term trend for Syndax Pharmaceuticals's investment purchases?
Over 4 years (2021 to 2025), Syndax Pharmaceuticals's investment purchases has grown at a -9.7% compound annual growth rate (CAGR), from $294.72M to $195.81M.
What does investment purchases mean?
Cash spent purchasing investment securities across all categories.